Sign up to save your podcasts
Or
Share Peter Lio, MD - More Than Scratching the Surface: Optimizing Novel JAK Inhibitors for Improved Outcomes in Moderate-to-Severe Atopic Dermatitis
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Peter Lio, MD - More Than Scratching the Surface: Optimizing Novel JAK Inhibitors for Improved Outcomes in Moderate-to-Severe Atopic Dermatitis
Please visit answersincme.com/FDH860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses the clinical evidence for novel Janus kinase (JAK) inhibitors for the treatment of moderate-to-severe atopic dermatitis. Upon completion of this activity, participants should be better able to: Describe the latest clinical evidence for novel JAK inhibitors in the treatment of moderate-to-severe AD; Outline practical strategies to manage adverse events associated with JAK inhibitors for the treatment of moderate-to-severe AD; and Identify patients with moderate-to-severe AD who might benefit from treatment with novel JAK inhibitors.
View all episodes
By Answers in CME
5
33 ratings
Please visit answersincme.com/FDH860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses the clinical evidence for novel Janus kinase (JAK) inhibitors for the treatment of moderate-to-severe atopic dermatitis. Upon completion of this activity, participants should be better able to: Describe the latest clinical evidence for novel JAK inhibitors in the treatment of moderate-to-severe AD; Outline practical strategies to manage adverse events associated with JAK inhibitors for the treatment of moderate-to-severe AD; and Identify patients with moderate-to-severe AD who might benefit from treatment with novel JAK inhibitors.